New medicine reduces triglyceride by 25%, no change in CVD risk in people with Type 2 diabetes – Yahoo Finance

Research Highlights:
A new cholesterol medication, pemafibrate, lowered triglyceride levels among adults with Type 2 diabetes, however, there was no decrease in the risk of cardiovascular events or death.
The medication reduced triglyceride levels by more than one-fourth, and patients were followed for up to 5 years.
In this high-risk study population, 1 out of 10 participants had either a heart attack, stroke, blocked arteries that required treatment or died from cardiovascular disease after about three years.
Embargoed until 10:02 a.m. CT/11:02 a.m. ET, Saturday, Nov. 5, 2022
This research is scheduled to simultaneously publish in the New England Journal of Medicine.
(NewMediaWire) – November 05, 2022 – CHICAGO A new medication, pemafibrate, lowered triglyceride levels among adults with Type 2 diabetes yet did not decrease their cardiovascular risk, according to late-breaking science research presented today at the American Heart Association's Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov. 5-7, 2022, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
"Triglyceride levels are commonly measured as part of routine preventive care in the U.S. Understanding the best course of treatment for elevated triglyceride levels has been a major challenge due to limited data to support specific treatment options," said the study's lead investigator Aruna D. Pradhan, M.D., M.P.H., M.Sc., an associate professor of medicine at Harvard Medical School and associate physician in the division of preventive medicine at Brigham and Women's Hospital in Boston.
"We were very surprised by our findings," Pradhan said. "Many of us in the scientific community thought lowering triglycerides with this medication class in this population should have worked because high triglycerides are a pretty good marker of who's at risk. Unfortunately, our results showed no lowering of cardiovascular event rates."
Triglycerides are a fatty substance in the blood. High triglyceride levels can increase the risk of cardiovascular disease, especially in conjunction with too much "bad" cholesterol, or low-density lipoprotein (LDL), and too little "good" cholesterol, or high-density lipoprotein (HDL).
Likewise, Type 2 diabetes also increases the risk of cardiovascular disease. In the U.S., about 28 million, or more than 1 in 10, adults have diagnosed Type 2 diabetes. Type 2 diabetes caused more than 1.6 million deaths worldwide in 2020, according to the American Heart Association's 2022 Heart and Stroke Statistical Update.
What remained unclear was whether lowering triglyceride levels may protect against cardiovascular disease among people with Type 2 diabetes. This study, Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT), examined the effects of pemafibrate, a novel medication designed to lower triglycerides and increase HDL levels.
Between March 2017 and September 2020, nearly 10,500 adults with high triglycerides, low HDL and Type 2 diabetes enrolled in the study in 24 countries, with one-fifth of participants in the U.S. They were randomly assigned to receive pemafibrate or placebo for three years, on average, and neither the researchers nor the study participants knew which group was receiving the medication or placebo.
The average age of participants was 64 years. Slightly more than one-fourth of study participants were women, and approximately 20% were Hispanic adults and 3% were Black adults. Nearly all were taking a statin to lower cholesterol. At the time of the study, half of participants had Type 2 diabetes for more than 10 years.
After three years, results indicate:
Pemafibrate reduced triglyceride levels by 26% compared to placebo. However, the medication did not appear to reduce the risk of cardiovascular disease.
Approximately 1 out of 10 study participants in both groups – had a heart attack, stroke, blocked arteries that required treatment or died from cardiovascular disease within three years.
The medication was also associated with an increase in LDL cholesterol during the trials.
"We need to find another solution to this problem," Pradhan said. "This medication class is the second most commonly used group, after statins, to lower lipid levels and while the medication did not increase CVD risk, the study raises new questions about the best way to treat patients with Type 2 diabetes and hypertriglyceridemia who continue to experience a high rate of cardiovascular events 1 in 10 by 3 years despite being on statin therapy and having fairly good control of LDL."
The study had several limitations: the medication did not lower triglycerides or increase HDL levels as much as expected, potentially due to the high proportion of statin use, and Black adults were underrepresented in the study.
Co-authors are Paul Ridker, M.D., M.P.H., FAHA, and PROMINENT Study Investigators. Authors' disclosures are listed in the abstract.
The study was funded by Kowa Company Limited (manufacturer of pemafibrate).
Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association's scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association's overall financial information are available here.
Additional Resources:
Multimedia is available on the right column of the release link https://newsroom.heart.org/news/new-medicine-reduces-triglyceride-by-25-no-change-in-cvd-risk-in-people-with-type-2-diabetes?preview=91e0b6c67f86e49c4803a18889aae99d
Link to abstract and AHA Scientific Session 2022 Online Program Planner
American Heart Association health information: What is diabetes?
AHA news release: Adding triglyceride-lowering Omega-3 based medication to statins may lower stroke risk (March 2021)
For more news at AHA Scientific Sessions 2022, follow us on Twitter @HeartNews #AHA22
The American Heart Association's Scientific Sessions 2022 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates occurring Saturday through Monday, November 5-7, 2022. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2022 on social media via #AHA22.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public's health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
###
For Media Inquiries and AHA Expert Perspective:
AHA Communications & Media Relations in Dallas: 214-706-1173; ahacommunications@heart.org
Bridgette McNeill: 214-706-1135; Bridgette.mcneill@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
Research Highlights: For people with stable chest pain, a personalized “precision” testing approach led to more efficient evaluations for heart disease risk and improved diagnosis and treatment of coronary artery disease when compared to usual care. …
Vanderbilt football will face South Carolina from FirstBank Stadium. Here are the live score updates.
It was because of the pandemic that Greg Mosse, husband of the bestselling author and playwright Kate, was finally able to write his first novel. His normal profession – playwright and theatre producer – had become entirely redundant in lockdown. Writing fiction had been on his mind, but he never had the time. But then suddenly he did.
The Eliza Fletcher murder reminded the nationwide running community that female runners face physical threats that male runners rarely face
Shares of Veru (NASDAQ: VERU) were skyrocketing 40.7% higher at 11:17 a.m. ET on Monday. The huge gain came after the U.S. Food and Drug Administration (FDA) released a briefing document related to Veru's Emergency Use Authorization (EUA) request for the COVID-19 drug sabizabulin. The FDA's Pulmonary-Allergy Drugs Advisory Committee Meeting to review this EUA request is scheduled for Nov. 9, 2022.
Veru stock skyrocketed Monday after the Food and Drug Administration posted a mixed review of its repurposed cancer drug for Covid treatment.
U.S. Food and Drug Administration staff said on Monday Veru Inc's experimental drug for COVID-19 met the main goal of reducing the death rate in a late-stage trial, but flagged a number of uncertainties with the data. Staff reviewers said the data did not help in clearly identifying a relevant patient population and remained unclear about the mortality rate in the placebo group. Veru has applied for emergency use authorization for its drug, sabizabulin, as a treatment for hospitalized moderate-to-severe COVID patients at high risk of developing an acute respiratory distress syndrome.
Amgen Inc (NASDAQ: AMGN) presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of olpasiran (formerly AMG 890) in adults with elevated lipoprotein levels and a history of atherosclerotic cardiovascular disease (ASCVD). These data were presented during the Nov. 6 Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions. Patients who received 75 mg or higher every 12 weeks had a 95% or greater reduction in lipoprotein levels compared to placebo at we
Staff reviewers at the U.S. Food and Drug Administration on Monday identified several uncertainties around Veru Inc's data for its experimental COVID-19 drug but did not raise any new concerns, sending its shares surging 52%. The reviewers also did not offer any strong argument against the emergency use authorization (EUA) even as they flagged the small size of the trial that showed the drug reduced death rates, analysts said. The data did not help clearly identify a relevant patient population and the high rate of deaths in a placebo group in the trial may raise questions about the results, the reviewers said.
A Watertown startup testing a drug licensed from Eli Lilly & Co. in midstage trials has filed for a $100 million IPO.
China's strict zero-COVID policy was making headlines Monday after Apple and iPhone manufacturer Foxconn said over the weekend that restrictions will delay shipments of the iPhone 14.
(Bloomberg) — VillageMD, the primary-care provider controlled by Walgreens Boots Alliance Inc., has agreed to acquire Summit Health-CityMD in an $8.9 billion deal that shows the drugstore operator expand deeper into health-care services to reduce its reliance on retail. Most Read from BloombergTwitter Now Asks Some Fired Workers to Please Come BackElon Musk Walks Back on Twitter Job Cuts, Blue Checks in Second WeekHouston Mogul’s $75 Million Win on Astros Hits Caesars HardestCOP27 Latest: Sunak
Village Practice Management would combine with Summit Health, the parent company of CityMD urgent-care centers, in an agreement that could be reached as early as Monday, people familiar with the matter said.
The psychologist recommended two strategies to do during the day to help better your sleep at night.
Your heart is one of the most central organs in your body, the main powerhouse controlling the flow of blood which affects every other organ and system. Plenty of lifestyle choices can help keep your heart in good working order, including eating a healthy diet and exercising regularly. Some folks may also take certain medicines, like statins or anti-clotting agents, to help their heart function the way it's supposed to.Many factors can contribute to potential heart failure, including certain med
Don't throw away your one shot.
LET’S UNPACK THAT: Studies have shown that the majority of men display signs of some form of body dysmorphia, while hyper-jacked actors such as Channing Tatum and Zac Efron have expressed regret over their unhealthy workout regimes. Are we in the midst of a male body-image crisis, asks Matthew Neale
Seventy percent of donor hearts go unused every year. A new device could change that.
What's covered by the government's health insurance program for seniors can be surprising.
Alcohol, including white wine, can be part of a healthy lifestyle if you choose to drink. According to the 2020-2025 Dietary Guidelines for Americans, if you opt to include alcohol in your diet, then it's suggested that you drink it in moderation.The recommendation for moderate consumption is up to 2 drinks per day for men and up to 1 drink per day for women. But what exactly is considered one drink of white wine and what happens to your body when you drink white wine on a nightly basis?One serv

source